+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multi-target MET TKIs Market by Indication (Gastric Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma), Line Of Therapy (First Line, Second Line, Third Line And Beyond), Distribution Channel, Formulation, Patient Age Group - Global Forecast 2025-2030- Product Image
Multi-target MET TKIs Market by Indication (Gastric Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma), Line Of Therapy (First Line, Second Line, Third Line And Beyond), Distribution Channel, Formulation, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Multi-target MET TKIs Market by Indication (Gastric Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma), Line Of Therapy (First Line, Second Line, Third Line And Beyond), Distribution Channel, Formulation, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129662
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Introduction to the Expanding Role of Multi-Target MET Tyrosine Kinase Inhibitors in Oncology Therapeutics Transforming Precision Oncology

The landscape of oncology therapeutics is witnessing a fundamental transformation as multi-target MET tyrosine kinase inhibitors (TKIs) emerge as a cornerstone of precision medicine. Through concurrent modulation of MET and ancillary signaling pathways, these agents address the complex biology underlying tumor proliferation, metastasis, and resistance mechanisms. In particular, aberrations in MET receptor activity have been implicated across a spectrum of solid tumors, stimulating a concerted effort to refine inhibitor selectivity, potency, and safety profiles.

Recent advances in medicinal chemistry and high-throughput screening have accelerated the evolution of next-generation multi-target MET TKIs. By integrating off-target kinase inhibition in a controlled manner, developers are equipping clinicians with agents capable of overcoming compensatory signaling that often undermines single-target therapies. Furthermore, the incorporation of predictive biomarkers into clinical trial designs has ushered in an era of patient stratification, enhancing response rates and maximizing therapeutic index.

As resistance to first-line treatments persists, the strategic deployment of multi-target MET TKIs holds the promise of durable disease control. This executive summary synthesizes key developments in drug discovery, regulatory milestones, and strategic imperatives, offering stakeholders a clear perspective on the opportunities and challenges that lie ahead.

Assessing Paradigm Shifts in Oncology Treatment Driven by Advancements in Multi-Target MET Inhibitor Research and Clinical Applications

Over the past decade, the oncology treatment paradigm has shifted from broad-spectrum cytotoxic regimens to mechanism-driven approaches centered on kinase inhibition. Multi-target MET TKIs exemplify this transformative trajectory by simultaneously disrupting MET-mediated oncogenic signaling and ancillary kinases that support tumor survival. As a result, these inhibitors are redefining response durability and reshaping clinical benchmark standards.

Moreover, the integration of next-generation sequencing and liquid biopsy technologies has accelerated trial enrollment and enriched study populations with MET-driven tumors. Consequently, recent approvals and breakthrough designations reflect a growing confidence in the safety and efficacy of multi-target MET TKIs across diverse tumor types. Additionally, strategic alliances between pharmaceutical leaders and biotech innovators are accelerating late-stage development programs and broadening the investigational pipeline.

In tandem with these clinical advances, payers and health technology assessment bodies are increasingly receptive to value propositions that demonstrate improved outcomes in refractory and high-unmet-need indications. Taken together, these shifts illustrate a rapidly evolving therapeutic landscape poised to deliver more personalized, combination-based regimens that leverage the unique advantages of multi-target MET inhibition.

Analyzing the Cumulative Impact of 2025 United States Tariffs on Global Supply Chains and Pricing Dynamics for Multi-Target MET Inhibitors

In 2025, the implementation of new United States tariffs has exerted considerable pressure on global pharmaceutical supply chains, notably impacting the production and distribution of specialized agents such as multi-target MET TKIs. Manufacturing facilities reliant on imported raw materials have faced increased input costs, compelling companies to reevaluate their procurement strategies and diversify sourcing to mitigate exposure to tariff fluctuations.

Furthermore, the resultant escalation in production expenses has translated into upward pricing pressures across various markets. In response, several manufacturers have explored localized manufacturing partnerships in tariff-exempt jurisdictions or have instituted tiered pricing agreements with regional distributors. These initiatives aim to preserve market access while safeguarding profit margins in an environment of heightened cost volatility.

Despite these challenges, stakeholders have leveraged the tariff-induced headwinds as an impetus to reinforce supply chain resilience. Investments in digital supply chain tracking, near-shoring of critical intermediates, and strategic inventory buffers have proven instrumental in sustaining product availability. Looking ahead, ongoing dialogue with regulatory authorities and trade negotiators remains critical to navigating future policy shifts and ensuring uninterrupted patient access to life-saving MET-targeted therapies.

Unlocking Comprehensive Market Segmentation Insights for Multi-Target MET TKIs Spanning Indication Lines Channels Formulations and Demographics

The oncology market for multi-target MET TKIs reveals distinct behavior across a range of clinical and commercial dimensions. When the analysis is structured according to indication, three primary tumor types-gastric cancer, non-small cell lung cancer, and renal cell carcinoma-emerge as the most intensively studied. Each indication subdivides into treatment lines: first-line patients often present de novo MET dysregulation, second-line cohorts represent acquired resistance following initial therapies, and third-line and beyond groups require more potent agents capable of addressing complex resistance patterns.

Shifting focus to line of therapy underscores the clinical imperative to position multi-target MET TKIs both early in treatment algorithms and as salvage options. Early-stage deployment can improve progression-free survival metrics, whereas later lines illustrate the capacity of these inhibitors to reestablish disease control after multiple prior regimens have failed.

Distribution channel analysis indicates that hospital pharmacies continue to anchor initial launches, leveraging institutional formularies and oncologist networks. However, retail pharmacies serve as a critical conduit for maintaining outpatient prescription volumes, and specialty pharmacies play an increasingly pivotal role in managing reimbursement complexities and patient adherence programs.

From a formulation perspective, capsules and tablets each offer distinct advantages in bioavailability, dosing flexibility, and patient tolerance. Capsule formulations often facilitate controlled release profiles, while tablets cater to stability and manufacturing scalability. Lastly, consideration of patient age group highlights divergent tolerability and comorbidity profiles, with adult patients generally exhibiting robust safety outcomes and elderly cohorts requiring tailored dosing and enhanced monitoring protocols.

Exploring Key Regional Dynamics and Strategic Growth Opportunities for Multi-Target MET TKIs across Americas Europe Middle East Africa and Asia Pacific

Across the Americas, a mature oncology infrastructure and well-established reimbursement frameworks have expedited the adoption of multi-target MET TKIs. Leading markets have streamlined regulatory pathways for targeted therapies, fostering robust clinical research networks and rapid integration of novel agents into standard care protocols.

In Europe, the Middle East & Africa region, heterogeneous healthcare systems and divergent reimbursement policies present both challenges and opportunities. While certain markets exhibit delayed access due to prolonged health technology assessments, other jurisdictions have instituted accelerated approval mechanisms for high-unmet-need therapies. Regional collaboration initiatives are increasingly facilitating cross-border trials and harmonizing access criteria.

Asia-Pacific markets demonstrate remarkable growth potential driven by rising cancer incidence, expanding public funding for oncology drugs, and strategic investments in biotechnology. Local manufacturers are forging partnerships with global developers to establish regional production hubs, thereby reducing lead times and optimizing cost structures. Meanwhile, emerging economies across the region are strengthening their regulatory capabilities, paving the way for broader inclusion of MET-targeted inhibitors in national formularies.

Evaluating Competitive Landscape and Strategic Initiatives Shaping the Leading Multi-Target MET Tyrosine Kinase Inhibitor Developers

The competitive environment for multi-target MET TKIs is distinguished by a mix of established pharmaceutical conglomerates and specialized biotechnology firms. Leading developers are pursuing differentiated strategies, including the refinement of chemical scaffolds to enhance selectivity and expansion of combination regimens with immunotherapies and antiangiogenic agents.

Strategic partnerships have become a hallmark of advancement, with several mid-stage clinical candidates securing co-development agreements that distribute risk and catalyze global trial enrollment. Meanwhile, priority review vouchers and breakthrough therapy designations have accelerated time to market for promising compounds, intensifying competition among first-to-file innovators.

Intellectual property portfolios are another critical battleground, as extended patent lifecycles and formulation patents can create meaningful exclusivity windows. In tandem, some mid-sized players are focusing on niche indications with high unmet need, thereby circumventing head-to-head competition and establishing strong footholds in select patient populations.

Overall, successful players are differentiating through robust clinical data packages, strategic lifecycle management plans, and proactive stakeholder engagement designed to address payer requirements and patient advocacy concerns.

Actionable Recommendations to Guide Industry Leaders in Optimizing Development Deployment and Adoption of Multi-Target MET Inhibitors

First, companies should prioritize the integration of comprehensive biomarker strategies into their clinical development programs. By establishing clear MET alteration thresholds and companion diagnostic partnerships early, sponsors can optimize patient selection and accelerate regulatory approval timelines.

Second, strengthening supply chain resilience is essential. Stakeholders should invest in geographically diversified manufacturing networks and digital traceability platforms to reduce tariff exposure and minimize potential shortages. Concurrently, strategic alliances with contract manufacturers can mitigate capital expenditure while ensuring consistent product quality.

Third, collaboration with payers is crucial to securing favorable reimbursement. Early engagement in health technology assessments and the development of robust real-world evidence frameworks will support value arguments and facilitate market access, particularly in regions with stringent cost-effectiveness requirements.

Finally, advancing combination trials that pair multi-target MET TKIs with immuno-oncology agents or targeted therapies offers a clear path to extending indications and prolonging patent protection. Such studies should be structured to generate translational insights, enabling adaptive trial designs that respond to emerging safety and efficacy data.

Detailed Research Methodology Outlining Data Collection Analytical Framework and Validation Processes Underpinning Multi-Target MET TKI Insights

This analysis is grounded in a hybrid research methodology that synthesizes primary and secondary data sources. Primary inputs include in-depth interviews with oncologists, clinical trial investigators, regulatory affairs specialists, and supply chain executives. These discussions provided qualitative insights into clinical needs, adoption barriers, and strategic priorities.

Secondary research encompassed a thorough review of peer-reviewed literature, conference abstracts, regulatory filings, and corporate disclosures. This comprehensive approach allowed for the triangulation of clinical efficacy data, safety profiles, and pipeline developments. Additionally, patent databases were examined to map intellectual property landscapes and identify emerging chemistry classes.

To validate findings, the research team applied an iterative framework combining thematic analysis with quantitative cross-verification. Data points were cross-checked against multiple sources, and discrepancies were resolved through follow-up consultations with subject matter experts. Finally, a rigorous peer review was conducted to ensure consistency, accuracy, and relevance of the insights presented.

Conclusion Synthesizing Key Findings and Strategic Implications for Future Innovation and Investment in Multi-Target MET Inhibitor Therapeutics

In summary, multi-target MET TKIs represent a pivotal advancement in targeted oncology, offering the potential to overcome resistance and improve outcomes across a spectrum of solid tumors. Scientific progress in biomarker-driven patient selection, coupled with strategic trial designs, has accelerated the clinical adoption of these agents.

Although external pressures such as tariff adjustments present challenges, proactive measures in supply chain diversification and pricing strategies have mitigated risks and preserved patient access. Moreover, the market’s segmentation across indications, therapy lines, distribution channels, formulations, and age groups underscores the versatility and broad applicability of multi-target MET inhibition.

Competitive dynamics are intensifying, with leading developers differentiating through robust pipeline progression, strategic alliances, and lifecycle management initiatives. Going forward, success will hinge on the ability to integrate real-world evidence, demonstrate compelling value propositions, and navigate evolving regulatory landscapes.

Ultimately, stakeholders who align research priorities, operational strategies, and commercialization efforts with these insights will be best positioned to capitalize on the transformative potential of multi-target MET TKIs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Gastric Cancer
      • First Line
      • Second Line
      • Third Line And Beyond
    • Non Small Cell Lung Cancer
      • First Line
      • Second Line
      • Third Line And Beyond
    • Renal Cell Carcinoma
      • First Line
      • Second Line
      • Third Line And Beyond
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line And Beyond
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Specialty Pharmacy
  • Formulation
    • Capsule
    • Tablet
  • Patient Age Group
    • Adult
    • Elderly
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Exelixis, Inc.
  • Ipsen S.A.
  • Pfizer Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Development of next-generation multi-target MET TKIs with improved brain penetration and CNS activity
5.2. Clinical evaluations of combination regimens pairing multi-target MET TKIs with PD-1 and PD-L1 inhibitors to enhance efficacy
5.3. Identification and management of acquired resistance mutations emerging during multi-target MET TKI therapy in NSCLC patients
5.4. Emerging real-world evidence on safety profiles and dose optimization strategies for multi-target MET TKI treatments across diverse populations
5.5. Strategic partnerships between biotech firms and academic institutions to accelerate multi-target MET TKI discovery and clinical translation
5.6. Regulatory approvals and label expansions for multi-target MET TKIs targeting rare MET exon 14 skipping mutations in solid tumors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multi-target MET TKIs Market, by Indication
8.1. Introduction
8.2. Gastric Cancer
8.2.1. First Line
8.2.2. Second Line
8.2.3. Third Line And Beyond
8.3. Non Small Cell Lung Cancer
8.3.1. First Line
8.3.2. Second Line
8.3.3. Third Line And Beyond
8.4. Renal Cell Carcinoma
8.4.1. First Line
8.4.2. Second Line
8.4.3. Third Line And Beyond
9. Multi-target MET TKIs Market, by Line Of Therapy
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Multi-target MET TKIs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Retail Pharmacy
10.4. Specialty Pharmacy
11. Multi-target MET TKIs Market, by Formulation
11.1. Introduction
11.2. Capsule
11.3. Tablet
12. Multi-target MET TKIs Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Elderly
13. Americas Multi-target MET TKIs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multi-target MET TKIs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multi-target MET TKIs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Exelixis, Inc.
16.3.2. Ipsen S.A.
16.3.3. Pfizer Inc.
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. MULTI-TARGET MET TKIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MULTI-TARGET MET TKIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MULTI-TARGET MET TKIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MULTI-TARGET MET TKIS MARKET: RESEARCHAI
FIGURE 26. MULTI-TARGET MET TKIS MARKET: RESEARCHSTATISTICS
FIGURE 27. MULTI-TARGET MET TKIS MARKET: RESEARCHCONTACTS
FIGURE 28. MULTI-TARGET MET TKIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MULTI-TARGET MET TKIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MULTI-TARGET MET TKIS MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES MULTI-TARGET MET TKIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 108. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 109. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 110. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 111. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 112. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 113. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 114. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 115. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 118. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 119. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 120. CANADA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 121. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 126. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 127. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 128. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 129. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 135. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 136. MEXICO MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 208. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 209. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 210. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 211. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 212. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 213. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 216. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 217. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 218. GERMANY MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 219. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 224. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 225. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 226. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 227. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 228. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 229. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 232. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 233. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 234. FRANCE MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 254. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 255. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 258. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 259. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 260. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 261. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 265. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. ITALY MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 272. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 273. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 274. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 275. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 276. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 277. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 280. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 281. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 282. SPAIN MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 313. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 314. SAUDI ARABIA MULTI-TARGET MET TKIS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA MULTI-TARGET MET TKIS MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Multi-target MET TKIs Market report include:
  • Exelixis, Inc.
  • Ipsen S.A.
  • Pfizer Inc.

Related Reports

Single-target MET TKIs Market by Product (Capmatinib, Savolitinib, Tepotinib), Indication (Gastric Cancer, Non Small Cell Lung Cancer), Therapy Line, Mutation Type, Mechanism, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Single-target MET TKIs Market by Product (Capmatinib, Savolitinib, Tepotinib), Indication (Gastric Cancer, Non Small Cell Lung Cancer), Therapy Line, Mutation Type, Mechanism, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
MET TKIs Market by Route Of Administration (Intravenous, Oral), Dosage Form (Capsule, Injection, Tablet), End User, Indication, Distribution Channel, Molecular Alteration - Global Forecast 2025-2030 - Product Image

MET TKIs Market by Route Of Administration (Intravenous, Oral), Dosage Form (Capsule, Injection, Tablet), End User, Indication, Distribution Channel, Molecular Alteration - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032 - Product Image

Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • 630 Pages
  • Global
From
Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034 - Product Image

Non-Small Cell Lung Cancer - Market Insight, Epidemiology, and Market Forecast -2034

  • Report
  • 880 Pages
  • Global
From
C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2025 - Product Image

C-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.